Elevating levels of the endocannabinoid 2-arachidonoylglycerol blunts opioid reward but not analgesia
Science Advances · 2024
DOI: 10.1126/sciadv.adq4779 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, 2024. Verfasst von Arlene Martínez-Rivera und 16 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatric Neurology, Department of Pediatrics, Weill Cornell Medicine, New York, NY 10065, USA. Hauptthemen laut MEDLINE: Endocannabinoids, Glycerides, Arachidonic Acids, Reward. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 84 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDA NIH HHS, NIMH NIH HHS.
Abstract (Originalsprache)
Converging findings have established that the endocannabinoid (eCB) system serves as a possible target for the development of new treatments as a complement to opioid-based treatments. Here, we show in male and female mice that enhancing levels of the eCB, 2-arachidonoylglycerol (2-AG), through pharmacological inhibition of its catabolic enzyme, monoacylglycerol lipase (MAGL), either systemically or in the ventral tegmental area (VTA) with JZL184, leads to a substantial attenuation of the rewarding effects of opioids in mice using conditioned place preference and self-administration paradigms, without altering their analgesic properties. These effects are driven by cannabinoid receptor 1 (CB1R) within the VTA, as VTA CB1R conditional knockout counteracts JZL184’s effects. Using fiber photometry with fluorescent sensors for calcium and dopamine (DA), we find that enhancing 2-AG levels diminishes opioid reward–related nucleus accumbens (NAc) activity and DA neurotransmission. Together, these findings reveal that 2-AG diminishes the rewarding properties of opioids and provides a potential adjunctive therapeutic strategy for opioid-related analgesic treatments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Pediatric Neurology, Department of Pediatrics, Weill Cornell Medicine, New York, NY 10065, USA.
- Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY 10065, USA.
- Center for Substance Abuse Research and Department of Neural Sciences, Lewis Katz School of Medicine at Temple University, Philadelphia, PA 19140, USA.
- Department of Psychiatry, Weill Cornell Medicine, New York, NY 10065, USA.
- Department of Psychology and Neuroscience Program, Temple University, Philadelphia, PA 19122, USA.
- Department of Anesthesiology, Rutgers New Jersey Medical School, Newark, NJ 07103, USA.
ORCID-Profile: Arlene Martínez-Rivera, Ruirong Yang, Narmin Mekawy, Kristen Pleil, Virginia M Pickel, Conor Liston, Joshua Levitz, Ying-Xian Pan, Lisa A Briand, Anjali M Rajadhyaksha, Francis S Lee
Förderung
- NIDA NIH HHS
- NIMH NIH HHS
Zitieren
APA
Martínez-Rivera, A., Fetcho, R. N., Birmingham, L., Xu, J., Yang, R., Foord, C., Scala-Chávez, D., Mekawy, N., Pleil, K., Pickel, V. M., Liston, C., Castorena, C. M., Levitz, J., Pan, Y. X., Briand, L. A., Rajadhyaksha, A. M., & Lee, F. S. (2024). Elevating levels of the endocannabinoid 2-arachidonoylglycerol blunts opioid reward but not analgesia. Science Advances. https://doi.org/10.1126/sciadv.adq4779
Vancouver
Martínez-Rivera A, Fetcho RN, Birmingham L, Xu J, Yang R, Foord C, et al. Elevating levels of the endocannabinoid 2-arachidonoylglycerol blunts opioid reward but not analgesia. Science Advances. 2024. doi:10.1126/sciadv.adq4779
BibTeX
@article{MartnezRivera2024,
author = {Martínez-Rivera, Arlene and Fetcho, Robert N and Birmingham, Lizzie and Xu, Jin and Yang, Ruirong and Foord, Careen and Scala-Chávez, Diego and Mekawy, Narmin and Pleil, Kristen and Pickel, Virginia M and Liston, Conor and Castorena, Carlos M and Levitz, Joshua and Pan, Ying-Xian and Briand, Lisa A and Rajadhyaksha, Anjali M and Lee, Francis S},
title = {Elevating levels of the endocannabinoid 2-arachidonoylglycerol blunts opioid reward but not analgesia},
journal = {Science Advances},
year = {2024},
doi = {10.1126/sciadv.adq4779}
}
EUVIMED